Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis
NCT ID: NCT00381264
Last Updated: 2008-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
23 participants
INTERVENTIONAL
2006-09-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MEsenchymal StEm Cells for Multiple Sclerosis
NCT01854957
Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
NCT00959218
Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis
NCT04178980
Duloxetine for Multiple Sclerosis Pain
NCT00755807
Melatonin in Patients With Multiple Sclerosis (MS).
NCT03498131
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a phase IV, multi-center, open label outpatient clinical trial evaluating Cesamet™ treatment for control of pain due MS. The study has two phases: a Pretreatment Phase and a Treatment Phase.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cesamet™ (nabilone)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic daily pain present for at least 2 months.
* On stable analgesic regimen for one month
* Baseline pain score greater than 40mm on a visual analog scale.
Exclusion Criteria
* Pregnant or lactating females
* Drug or alcohol abuse
* Unstable medical condition
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NEMA Research, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
NEMA Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph V Pergolizzi, MD
Role: PRINCIPAL_INVESTIGATOR
NEMA Research, Inc.
Charlotte A Richmond, PhD
Role: STUDY_DIRECTOR
Nema Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Florida Medical Research
Aventura, Florida, United States
Sunrise Clinical Research, Inc.
Hollywood, Florida, United States
Naples Anesthesia and Pain Associates
Naples, Florida, United States
Lazlo Mate, MD
West Palm Beach, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Nema Research website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CB1 Study 002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.